Explore by Category

Oncopeptides Launches Expanded Access Melflufen Program for Multiple Myeloma Patients

MYELOMA NEWS - October 01, 2020

Oncopeptides has launched their United States Expanded Access Program with melflufen (also called Melphalan Flufenamide) for relapsed or refractory patients who... Read More

Tandem Transplants vs. Auto-Allo Transplants in Multiple Myeloma

MYELOMA NEWS - September 30, 2020

Which is better, two back-to-back autologous stem cell transplants or one auto followed by one allo (donor) transplant? Myeloma researcher Luciano Costa, M... Read More

FDA Grants Priority Review for Ide-Cel CAR T Therapy

MYELOMA NEWS - September 28, 2020

In a recent press release, Bristol Myers Squibb and bluebird bio announced that the FDA has accepted the new drug application for ide-cel (idecabtagene vicleuce... Read More

FDA Grants Orphan Drug Status to New CD38 Antibody Redirecting Molecule (ARM) Myeloma Therapy

MYELOMA NEWS - September 18, 2020

The FDA has granted Orphan Drug designation to a new type of myeloma therapy called an Antibody Redirecting Molecule (ARM) targeting CD38. The orphan drug ... Read More

MRD Negativity is Better than Stringent Complete Response (sCR) to Determine Myeloma Patient Outcomes

MYELOMA NEWS - September 17, 2020

In a head-to-head study comparing minimal residual disease (MRD) testing vs. using the "stringent complete response" measurement, MRD indicated a more... Read More

New Ways to Use Our Own T Cells to Treat Myeloma

MYELOMA NEWS - September 14, 2020

Most of us have been reading about CAR-T treatments over the past few years to treat a variety of hematological malignancies. Two CAR-T products have been on th... Read More

Ninlaro with Dex and Revlimid Extends Survival for Newly Diagnosed, Transplant Ineligible Myeloma Patients

MYELOMA NEWS - September 11, 2020

New study results showed that the triplet combination including Ninlaro, lenalidomide and dex increased progression free survival for newly diagnosed myeloma pa... Read More

More Good News for Newly Diagnosed, High Risk Myeloma Patients

MYELOMA NEWS - September 11, 2020

Unfortunately, some of us are or have been tagged as high-risk myeloma patients (and I am one of them). There is some good news that has been reported from Germ... Read More

New Rules for the Centers for Medicare and Medicaid Services on CAR T Therapy

MYELOMA NEWS - September 04, 2020

The Centers for Medicare and Medicaid Services (CMS) recently approved new rules for the use of CAR T treatment for Medicare and Medicaid payment... Read More

Expanded Access in the United States: What Does It Mean & Its Role In Future Drug Development

MYELOMA NEWS - September 01, 2020

Jess Rabourn of Ax-S Pharma, LLC provides an overview on the principles and practices of Expanded Access programs Patients are frustrated. And their doctor... Read More

The Best Dose of Lenalidomide as Maintenance Therapy in Multiple Myeloma

MYELOMA NEWS - August 24, 2020

In the first study of high dose vs. low dose lenalidomide maintenance, German researchers found that a 10-15mg dose of lenalidomide was most effective in e... Read More

FDA Clears New Use of Kyprolis with Daratumuamb and Dex for Relapsed Multiple Myeloma Patients

MYELOMA NEWS - August 20, 2020

Today the FDA approved the use of Kyprolis (carfilzomib) in a new combination with DARZALEX (daratumumab) and dexamethasone (also called DKd). The approval cove... Read More

How IVig Boosts the Immune System and Kills Multiple Myeloma

MYELOMA NEWS - August 19, 2020

Myeloma patients can often have low levels of normal antibodies that fight infection. Those low levels can lead to issues with recurring infections. If antibody... Read More

Thanks to our Myeloma Crowd Community sponsors: